Policy alternatives for treatments for rare diseases
- Drug reimport won't save much, study finds. // Drug Topics;5/17/2004, Vol. 148 Issue 10, p10
Reports that according to an issue brief from the U.S. Congressional Budget Office, allowing reimportation of U.S.-made medications would reduce drug spending by only about one percent.
- Abstracts of China's Laws and Regulations Related to Pharmaceutical Sector. // China Chemical Reporter;1/26/2009, Vol. 20 Issue 3, p7
The article provides an overview of China's pharmaceutical policy. According to the Drug Administration Law of China that took effect on January 7, 2009, any drug-making company must be approved by authorities at provincial, autonomous regional or municipal levels, and must obtain a production...
- PRICE COMPETITION AND THE EFFICACY OF PRESCRIPTION DRUGS: CONFLICTING OBJECTIVES? Jadlow, Joseph M. // Nebraska Journal of Economics & Business;Autumn72, Vol. 11 Issue 4, p121
Examines the effect of the 1962 drug amendments on price competition in drug markets in the U.S. Goals of the amendments; Impact of the amendments on drug research costs; Influence of the amendment on drug development; Description of the drug market in the country.
- Tracking the Pulse of the Pharmaceutical Industry. Siew, Adeline // Pharmaceutical Technology Europe;Aug2014, Vol. 26 Issue 8, p6
An introduction is presented for the issue which discusses 25 years of pharmaceutical industry in Europe, views of several experts for advancements of technology in drug development and changes in European medicine regulations.
- REPURPOSING & COLLABORATIVE DRUG DEVELOPMENT FOR RARE DISEASES. MUTHYALA, RAMAIAH // Marquette Intellectual Property Law Review;Winter2014, Vol. 18 Issue 1, p25
The article focuses on repurposing & collaborative drug development for rare diseases. Topics discussed include significance of orphan drug development, the U.S. Orphan Drug Act (ODA) due to which pharmaceutical firms are willing to develop drugs for rare diseases and drug repurposing activity...
- LEKOVI â€žSIROÄŒIÄ†I". GOLOČORBIN KON, Svetlana; VOJINOVIĆ, Aleksandra; LALIĆ-POPOVIĆ, Mladena; PAVLOVIĆ, Nebojša; MIKOV, Momir // Medicinski Pregled / Medical Review;sep/okt2013, Vol. 66 Issue 9/10, p373
Introduction. Drugs used for treatment of rare diseases are known worldwide under the term of orphan drugs because pharmaceutical companies have not been interested in "adopting" them, that is in investing in research, developing and producing these drugs. This kind of policy has been justified...
- Orphan drug pricing may warrant a competition law investigation. Roos, Jonathan C. P.; Hyry, Hanna I.; Cox, Timothy M. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;11/20/2010, Vol. 341 Issue 7782, p1084
In this article, the authors argue that pricing hinders pharmaceutical companies to develop orphan drugs. The authors add that the European legislation on orphan drug makes exclusive marketing period as an incentive for companies to develop drugs for rare diseases. However, they argue that the...
- The Role of Academic Institutions in the Development of Drugs for Rare and Neglected Diseases. Coles, L D; Cloyd, J C // Clinical Pharmacology & Therapeutics;Aug2012, Vol. 92 Issue 2, p193
There are approximately 7,000 rare disorders, many of which are life-threatening. Diagnosis is often problematic, and therapies are few. Before the passage of the Orphan Drug Act in 1983, neither the pharmaceutical industry nor universities devoted much effort to research on rare diseases....
- EU adopts legislation to promote drug development for rare diseases. Whyte, Barry // Bulletin of the World Health Organization;2000, Vol. 78 Issue 5, p711
Reports that the European Union (EU) Executive Commission adopted legislation to stimulate the development of drugs for rare disease. Applications of the pharmaceutical companies to the European Agency for the Evaluation of Medicinal Products (EMEA); Comments of executive director of the EMEA...